Trevi Therapeutics
General Information
Listing Information
Category
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.
Source: 1Fortune 500, 2026. 2U.S. Census Bureau, ACS 1Y, 2024—released Sep 2025. 3WalletHub, 2026. 4WalletHub, 2026. 5U.S. Bureau of Economic Analysis, 2025; U.S. Bureau of Labor Statistics State and Area Employment, 2025; AdvanceCT calculations.
Key Facts
#3
highest percentage of adults with graduate or professional degrees2
#3
best community college system in the country3
#4
most educated workforce4
#6
most productive workforce5
